Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myositis in children.

A M Reed1

  • 1Pediatrics, Mayo Clinic, Rochester, Minnesota 55905, USA. reed.ann18@Mayo.edu

Current Opinion in Rheumatology
|October 18, 2001
PubMed
Summary
This summary is machine-generated.

Recent advances improve understanding and treatment of childhood idiopathic inflammatory myositis, primarily juvenile dermatomyositis and juvenile polymyositis. New insights into epidemiology, pathogenesis, and therapies offer better care with reduced toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Examining the Diagnostic Accuracy of a Novel Performance-Based Test for Alzheimer's Disease Screening.

The journal of prevention of Alzheimer's disease..·2024
Same author

Juvenile idiopathic arthritis and future risk for cardiovascular disease: a multicenter study.

Scandinavian journal of rheumatology·2016
Same author

Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes.

Genes and immunity·2015
Same author

Use of atorvastatin in systemic lupus erythematosus in children and adolescents.

Arthritis and rheumatism·2011
Same author

Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort.

Lupus·2010
Same author

The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy.

Rheumatology (Oxford, England)·2007
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Genetics

Background:

  • Idiopathic inflammatory myositis in children encompasses juvenile dermatomyositis and juvenile polymyositis.
  • Recent research has significantly expanded knowledge on these conditions.

Purpose of the Study:

  • To review recent findings on the epidemiology, pathogenesis, diagnosis, and treatment of childhood idiopathic inflammatory myositis.
  • To highlight advancements in understanding immune responses and genetic associations.

Main Methods:

  • Literature review of recent publications on pediatric idiopathic inflammatory myositis.
  • Synthesis of new data on disease onset, triggers, regional variations, and genetic factors.

Main Results:

Related Experiment Videos

  • New information on epidemiology, pathogenesis, and clinical presentation.
  • Emerging data on immune response gene associations and chimerism.
  • Advances in clinical evaluation, outcome assessment, and treatment protocols.

    • Conclusions:

    • Significant progress has been made in understanding and managing childhood idiopathic inflammatory myositis.
    • New treatment protocols aim for more effective therapy with reduced toxicity.
    • Continued research is essential for further understanding and improved patient care.